P
77.85
1.16 (1.51%)
| Previous Close | 76.69 |
| Open | 77.21 |
| Volume | 810,565 |
| Avg. Volume (3M) | 1,112,785 |
| Market Cap | 4,843,151,360 |
| Price / Earnings (TTM) | 106.64 |
| Price / Earnings (Forward) | 26.39 |
| Price / Sales | 20.11 |
| Price / Book | 6.05 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 27.04% |
| Operating Margin (TTM) | -68.18% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | -88.90% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 17.25 |
| Operating Cash Flow (TTM) | 336.94 M |
| Levered Free Cash Flow (TTM) | 327.76 M |
| Return on Assets (TTM) | 2.48% |
| Return on Equity (TTM) | 8.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Protagonist Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 108.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 102.00 (Citizens, 31.02%) | Buy |
| Median | 86.00 (10.47%) | |
| Low | 73.00 (Leerink Partners, -6.23%) | Buy |
| Average | 86.44 (11.03%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 75.32 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 10 Nov 2025 | 98.00 (25.88%) | Buy | 79.54 |
| 17 Oct 2025 | 96.00 (23.31%) | Buy | 77.50 | |
| Barclays | 07 Nov 2025 | 88.00 (13.04%) | Buy | 79.54 |
| 17 Sep 2025 | 72.00 (-7.51%) | Buy | 59.22 | |
| Citizens | 07 Nov 2025 | 102.00 (31.02%) | Buy | 79.54 |
| JP Morgan | 07 Nov 2025 | 81.00 (4.05%) | Buy | 79.54 |
| BTIG | 28 Oct 2025 | 82.00 (5.33%) | Buy | 78.51 |
| Truist Securities | 28 Oct 2025 | 88.00 (13.04%) | Buy | 78.51 |
| Wedbush | 28 Oct 2025 | 86.00 (10.47%) | Buy | 78.51 |
| HC Wainwright & Co. | 08 Oct 2025 | 80.00 (2.76%) | Buy | 65.30 |
| 17 Sep 2025 | 80.00 (2.76%) | Buy | 59.22 | |
| Leerink Partners | 12 Sep 2025 | 73.00 (-6.23%) | Buy | 58.86 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |